Metrics to compare | CESSA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCESSAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −36.0x | 9.6x | −0.5x | |
PEG Ratio | −0.83 | −0.41 | 0.00 | |
Price/Book | 39.1x | 1.8x | 2.6x | |
Price / LTM Sales | 79.1x | 1.0x | 3.0x | |
Upside (Analyst Target) | - | 25.1% | 58.6% | |
Fair Value Upside | Unlock | 14.6% | 10.2% | Unlock |
Cessatech A/S, a pivotal-stage pediatric biotech company, develops specialty hospital medicines for children in Denmark. Its lead candidate product is CT001, a fixed-dose nasal spray for treating acute pain in children. The company also develops CT002, a non-invasive intranasal sedation for children undergoing medical procedures in Phase 2 clinical trials; and CT003, a topical anesthetic in pre-clinical development. The company has a collaboration with University Hospital of Copenhagen, Rigshospitalet, to advance an intravenous formulation of melatonin for post-anaesthesia delirium (CT004) in children. Cessatech A/S was incorporated in 2020 and is based in Copenhagen, Denmark.